Dyschromicum Perstans: A Comprehensive Review of Clinical Indicators, Disease Activity, and Treatment Implications

Background: Erythema dyschromicum perstans (EDP) is an acquired, slowly progressive dermal hyperpigmentation that produces ash- grey to blue-grey macules, predominantly in patients with intermediate to dark skin phototypes. A transient erythematous border, interface inflammation and pigment incontinence are described, but most patients are seen with persistent grey macules. Whether a given lesion is still inflamed, or merely retains dermal pigment from earlier injury, is rarely documented, yet the distinction underlies treatment choice and the interpretation of treatment response. Objective: To examine whether clinical, dermoscopic, histopathological and longitudinal findings can distinguish ongoing inflammatory activity from residual pigmentation in EDP, and how this distinction should inform treatment selection, response assessment and follow-up. Evidence synthesis: PubMed (all 233 records indexed under 'erythema dyschromicum perstans' or 'ashy dermatosis'), Crossref, publisher and registry sources were searched to 26 October 2026, with backward citation chasing. Studies were classified by diagnostic terminology (EDP, ashy dermatosis, acquired dermal macular hyperpigmentation [ADMH], lichen planus pigmentosus, mixed), and each candidate activity marker was graded by the directness of its evidence. Key findings: No validated EDP-specific activity definition, activity score or histological staging system was identified. The erythematous border, which consensus terminology ties to an 'active stage', was present in only 17.6% of 68 Korean patients. New or enlarging lesions are the most pragmatic activity indicators; in an ADMH trial using this definition, stabilisation occurred after a mean of about 6 weeks, whereas pigment severity first fell significantly at week 16. Cross-sectional biopsies describe interface change and lymphocytic infiltrates in early or bordered lesions and melanophage-predominant pigment later, but no study has followed the same lesion histologically. A pinkish-brown dermoscopic background was linked to early lesions in one small series. Treatment evidence consists largely of case reports and small uncontrolled series that seldom record baseline activity or separate suppression of new lesions from pigment clearance. Conclusion: Persistent pigmentation does not by itself indicate ongoing inflammation, and absence of erythema does not exclude microscopic activity. Until prospective, activity-stratified studies exist, clinicians and investigators should document activity (new lesions, enlargement, border erythema) separately from pigment severity and should report these outcomes independently.

Authors

Publication Details

Journal
HAL
Published
2026-11-14
DOI
https://doi.org/10.59324/jcpmr.2026.2(6).07
Primary Topic
melanin and skin pigmentation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dyschromicum Perstans: A Comprehensive Review of Clinical Indicators, Disease Activity, and Treatment Implications

Saud Abdullah Ali Alsharif
HAL
melanin and skin pigmentation
article

Dyschromicum Perstans: A Comprehensive Review of Clinical Indicators, Disease Activity, and Treatment Implications

Saud Abdullah Ali Alsharif
article en

Abstract

Background: Erythema dyschromicum perstans (EDP) is an acquired, slowly progressive dermal hyperpigmentation that produces ash- grey to blue-grey macules, predominantly in patients with intermediate to dark skin phototypes. A transient erythematous border, interface inflammation and pigment incontinence are described, but most patients are seen with persistent grey macules. Whether a given lesion is still inflamed, or merely retains dermal pigment from earlier injury, is rarely documented, yet the distinction underlies treatment choice and the interpretation of treatment response. Objective: To examine whether clinical, dermoscopic, histopathological and longitudinal findings can distinguish ongoing inflammatory activity from residual pigmentation in EDP, and how this distinction should inform treatment selection, response assessment and follow-up. Evidence synthesis: PubMed (all 233 records indexed under 'erythema dyschromicum perstans' or 'ashy dermatosis'), Crossref, publisher and registry sources were searched to 26 October 2026, with backward citation chasing. Studies were classified by diagnostic terminology (EDP, ashy dermatosis, acquired dermal macular hyperpigmentation [ADMH], lichen planus pigmentosus, mixed), and each candidate activity marker was graded by the directness of its evidence. Key findings: No validated EDP-specific activity definition, activity score or histological staging system was identified. The erythematous border, which consensus terminology ties to an 'active stage', was present in only 17.6% of 68 Korean patients. New or enlarging lesions are the most pragmatic activity indicators; in an ADMH trial using this definition, stabilisation occurred after a mean of about 6 weeks, whereas pigment severity first fell significantly at week 16. Cross-sectional biopsies describe interface change and lymphocytic infiltrates in early or bordered lesions and melanophage-predominant pigment later, but no study has followed the same lesion histologically. A pinkish-brown dermoscopic background was linked to early lesions in one small series. Treatment evidence consists largely of case reports and small uncontrolled series that seldom record baseline activity or separate suppression of new lesions from pigment clearance. Conclusion: Persistent pigmentation does not by itself indicate ongoing inflammation, and absence of erythema does not exclude microscopic activity. Until prospective, activity-stratified studies exist, clinicians and investigators should document activity (new lesions, enlargement, border erythema) separately from pigment severity and should report these outcomes independently.

HALVol. 2(6)
melanin and skin pigmentation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon